Cargando…

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients

OBJECTIVE: The present study investigated long-term outcomes of medroxyprogesterone acetate (MPA) plus metformin therapy in terms of control of atypical endometrial hyperplasia (AEH) and endometrial cancer (EC), and post-treatment conception. METHODS: We retrospectively analyzed 63 patients (42 with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitsuhashi, Akira, Habu, Yuji, Kobayashi, Tatsuya, Kawarai, Yoshimasa, Ishikawa, Hiroshi, Usui, Hirokazu, Shozu, Makio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779615/ https://www.ncbi.nlm.nih.gov/pubmed/31576686 http://dx.doi.org/10.3802/jgo.2019.30.e90

Ejemplares similares

Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial)
por: Mitsuhashi, Akira, et al.
Publicado: (2020)

Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer
por: Gu, Wenjing, et al.
Publicado: (2022)

Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity
por: Chen, Junyu, et al.
Publicado: (2022)

Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021)

Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis
por: Shao, Fengping, et al.
Publicado: (2023)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin as a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma
por: Jing, Chu-Yu, et al.
Publicado: (2022)

Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer
por: Hanawa, Shinsuke, et al.
Publicado: (2018)

The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer
por: Guan, Jun, et al.
Publicado: (2022)

Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy
por: Chen, Junyu, et al.
Publicado: (2021)

Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions
por: Contreras, Nayanar-Adela, et al.
Publicado: (2022)

Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy
por: Ga, Hiromi, et al.
Publicado: (2023)

Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma
por: Newtson, A.M., et al.
Publicado: (2017)

Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?
por: Baek, Ji Sun, et al.
Publicado: (2016)

Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology
por: Ushijima, Kimio, et al.
Publicado: (2023)

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
por: Lv, Mu, et al.
Publicado: (2022)

Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol
por: Zhao, Xin, et al.
Publicado: (2022)

Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia
por: Shan, Weiwei, et al.
Publicado: (2014)

Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients
por: Yang, Bingyi, et al.
Publicado: (2018)

Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience
por: Shikeli, Sumaya, et al.
Publicado: (2020)

Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review
por: Murakami, Isao, et al.
Publicado: (2023)

The effect of steep head-down tilt on respiratory status in endometrial cancer patients with obesity during robot-assisted hysterectomy
por: Mitsuhashi, Akira, et al.
Publicado: (2022)

Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia
por: Fan, Yuan, et al.
Publicado: (2021)

Fertility-sparing treatment for endometrial cancer and atypical endometrial hyperplasia in patients with Lynch Syndrome: Molecular diagnosis after immunohistochemistry of MMR proteins
por: Catena, Ursula, et al.
Publicado: (2022)

Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia
por: Zhang, Xiaobo, et al.
Publicado: (2022)

Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis
por: Li, Miaomiao, et al.
Publicado: (2019)

Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Ding, Yingqiao, et al.
Publicado: (2022)

Effects of Weight Status and Related Metabolic Disorders on Fertility-Sparing Treatment Outcomes in Endometrial Atypical Hyperplasia and Endometrial Cancer: A Retrospective Study
por: Liu, Sijia, et al.
Publicado: (2022)

Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia
por: Zhang, Qing, et al.
Publicado: (2017)

Progesterone as a Postnatal Prophylactic Agent for Encephalopathy Caused by Prenatal Hypoxic Ischemic Insult
por: Kawarai, Yoshimasa, et al.
Publicado: (2018)

Effect and Management of Excess Weight in the Context of Fertility-Sparing Treatments in Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer: Eight-Year Experience of 227 Cases
por: Shan, Ying, et al.
Publicado: (2021)

Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study
por: Wang, Yiqin, et al.
Publicado: (2021)

Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
por: Gertz, Jay, et al.
Publicado: (2021)

Identification of potential models for predicting progestin insensitivity in patients with endometrial atypical hyperplasia and endometrioid endometrial cancer based on ATAC-Seq and RNA-Seq integrated analysis
por: Hu, Jia-Li, et al.
Publicado: (2022)

Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review
por: Wei, Jing, et al.
Publicado: (2017)

Clinical implications of morular metaplasia in fertility-preserving treatment for atypical endometrial hyperplasia and early endometrial carcinoma patients
por: Wu, Pengfei, et al.
Publicado: (2022)

Development of localized cul-de-sac endometrioid carcinoma associated with deep infiltrating endometriosis during remission of early endometrial cancer
por: Seki, Kumiko, et al.
Publicado: (2019)

Fertility-Sparing Treatment and Assisted Reproductive Technology in Patients with Endometrial Carcinoma and Endometrial Hyperplasia: Pregnancy Outcomes after Embryo Transfer
por: Friedlander, Hilary, et al.
Publicado: (2023)

Metformin for endometrial hyperplasia: a Cochrane protocol
por: Clement, Naomi S, et al.
Publicado: (2016)

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer
por: Holland, C M, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_hav4t4224hghg2pog7jtpdp4ta